Please assess the completion status of the following clinical trial:

Trial Title: PK/PD of EA-230 During Endotoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 to 35 years inclusive~2. For part 2 only male~3. Subjects and their partners use a reliable way of contraception~4. BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg~5. Healthy as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory parameters~Exclusion Criteria:~1. Unwillingness to abstain from any medication, recreational drugs or anti-oxidant vitamin supplements during the course of the study and within 7 days prior to study Day 1.~2. Unwillingness to abstain from nicotine, or alcohol or within 1 day prior to study Day 1~3. Previous participation in a trial where LPS was administered~4. Surgery or trauma with significant blood loss or blood donation within 3 months prior to study Day 1~5. History, signs or symptoms of cardiovascular disease, in particular:~   * History of frequent vaso-vagal collapse or of orthostatic hypotension~  * Resting pulse rate ≤45 or ≥100 beats / min~  * Hypertension (RR systolic \>160 or RR diastolic \>90)~  * Hypotension (RR systolic \<100 or RR diastolic \<50)~  * conduction abnormalities on the ECG~6. Renal impairment: plasma creatinine \>120 µmol/L~7. Liver function tests (alkaline phosphatase, AST, ALT and/or γ-GT) above 2x the upper limit of normal.~8. History of asthma~9. Atopic constitution~10. CRP above 2x the upper limit of normal, or clinically significant acute illness, including infections, within 2 weeks before administration of the study drug.~11. Treatment with investigational drugs or participation in any other clinical trial within 30 days prior to study drug administration.~12. Known or suspected of not being able to comply with the trial protocol.~13. Known hypersensitivity to any excipients of the drug formulations used.~14. Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- EA-230 (30mg/kg) (Type: ACTIVE_COMPARATOR): Subjects will receive EA-230, 30 mg/kg
- EA-230 (90mg/kg) (Type: ACTIVE_COMPARATOR): Subjects will receive EA-230, 90 mg/kg
- EA-230 (180mg/kg) (Type: ACTIVE_COMPARATOR): Subjects will receive EA-230, 180 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): subjects receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).